[go: up one dir, main page]

NO20091198L - Azabenzotiofenylforbindelser og anvendelser derav - Google Patents

Azabenzotiofenylforbindelser og anvendelser derav

Info

Publication number
NO20091198L
NO20091198L NO20091198A NO20091198A NO20091198L NO 20091198 L NO20091198 L NO 20091198L NO 20091198 A NO20091198 A NO 20091198A NO 20091198 A NO20091198 A NO 20091198A NO 20091198 L NO20091198 L NO 20091198L
Authority
NO
Norway
Prior art keywords
compounds
azabenzothiophenyl
treat
methods
relates
Prior art date
Application number
NO20091198A
Other languages
English (en)
Norwegian (no)
Inventor
Mark S Stanley
Hazel Joan Dyke
Stephen Price
Karen Williams
Liang Bao
John Gary Montana
Pascal Pierre Savy
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38800915&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20091198(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of NO20091198L publication Critical patent/NO20091198L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4743—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20091198A 2006-08-21 2009-03-20 Azabenzotiofenylforbindelser og anvendelser derav NO20091198L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US83916306P 2006-08-21 2006-08-21
US87160006P 2006-12-22 2006-12-22
US91762407P 2007-05-11 2007-05-11
PCT/US2007/076340 WO2008024724A1 (en) 2006-08-21 2007-08-20 Aza-benzothiophenyl compounds and methods of use

Publications (1)

Publication Number Publication Date
NO20091198L true NO20091198L (no) 2009-05-20

Family

ID=38800915

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091198A NO20091198L (no) 2006-08-21 2009-03-20 Azabenzotiofenylforbindelser og anvendelser derav

Country Status (16)

Country Link
US (1) US7893085B2 (es)
EP (1) EP2069359B1 (es)
JP (1) JP5349306B2 (es)
KR (1) KR101475088B1 (es)
AR (1) AR062469A1 (es)
AU (1) AU2007286807B2 (es)
BR (1) BRPI0714629A2 (es)
CA (1) CA2660963A1 (es)
CL (1) CL2007002431A1 (es)
ES (1) ES2528797T3 (es)
IL (1) IL197060A (es)
MX (1) MX2009001875A (es)
NO (1) NO20091198L (es)
PE (2) PE20120049A1 (es)
TW (1) TWI426078B (es)
WO (1) WO2008024724A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008024725A1 (en) * 2006-08-21 2008-02-28 Genentech, Inc. Aza-benzofuranyl compounds and methods of use
WO2010068738A1 (en) 2008-12-10 2010-06-17 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
WO2011106298A1 (en) 2010-02-25 2011-09-01 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors
AU2011224410B2 (en) 2010-03-09 2015-05-28 Dana-Farber Cancer Institute, Inc. Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy
EP2844655A1 (en) 2012-05-02 2015-03-11 Lupin Limited Substituted pyridine compounds as crac modulators
US20150141470A1 (en) 2012-05-08 2015-05-21 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
AU2013337702A1 (en) 2012-11-02 2015-05-21 Merck Patent Gmbh Method of reducing adverse effects in a cancer patient undergoing treatment with a MEK inhibitor
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
US20170114323A1 (en) 2014-06-19 2017-04-27 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
GB201508026D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Capsid
AU2016378723B2 (en) * 2015-12-22 2021-09-30 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
MX2018012471A (es) 2016-04-15 2019-02-21 Genentech Inc Metodos de diagnostico y terapeuticos para el cancer.
ES3030506T3 (en) 2017-05-19 2025-06-30 Nflection Therapeutics Inc Pyrrolopyridine-aniline compounds for treatment of dermal disorders
ES2913213T3 (es) * 2017-05-19 2022-06-01 Nflection Therapeutics Inc Compuestos heteroaromáticos de anilina condensados para el tratamiento de trastornos dérmicos
MA49458A (fr) 2017-06-21 2020-04-29 SHY Therapeutics LLC Composés interagissant avec la superfamille ras destinés à être utilisés dans le traitement de cancers, de maladies inflammatoires, de rasopathies et de maladies fibrotiques
TW202428305A (zh) 2017-09-08 2024-07-16 美商建南德克公司 癌症之診斷及治療方法
US20210008047A1 (en) 2018-02-13 2021-01-14 Vib Vzw Targeting minimal residual disease in cancer with rxr antagonists
IL279977B2 (en) 2018-07-09 2024-06-01 Boehringer Ingelheim Animal Health Usa Inc Heterocyclic anthelmintic compounds
MA55144A (fr) 2018-11-20 2021-09-29 Nflection Therapeutics Inc Composés naphthyridinone-aniline destinés au traitement d'affections de la peau
EP3883552B1 (en) 2018-11-20 2025-04-09 NFlection Therapeutics, Inc. Cyanoaryl-aniline compounds for treatment of dermal disorders
WO2020106305A1 (en) 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Thienyl-aniline compounds for treatment of dermal disorders
EP3898609A1 (en) 2018-12-19 2021-10-27 Shy Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
CA3133100A1 (en) 2019-03-19 2020-09-24 Boehringer Ingelheim Animal Health USA Inc. Anthelmintic aza-benzothiophene and aza-benzofuran compounds
MX2022015038A (es) 2020-05-29 2023-01-04 Boehringer Ingelheim Animal Health Usa Inc Compuestos heterociclicos como anthelminticos.
US12371667B2 (en) 2021-05-13 2025-07-29 Washington University Enhanced methods for inducing and maintaining naive human pluripotent stem cells
IL312412A (en) 2021-11-01 2024-06-01 Boehringer Ingelheim Vetmedica Gmbh Pyrrolopyridazine compounds against worms
WO2024033381A1 (en) 2022-08-10 2024-02-15 Vib Vzw Inhibition of tcf4/itf2 in the treatment of cancer

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5328920A (en) * 1991-04-17 1994-07-12 Hoechst-Roussel Pharmaceuticals Incorporated Substituted (pyridinylamino)-indoles
WO1993001169A2 (en) 1991-07-05 1993-01-21 Merck Sharp & Dohme Limited Aromatic compounds, pharmaceutical compositions containing them and their use in therapy
US5214204A (en) * 1991-07-19 1993-05-25 Abbott Laboratories Arylamidoalkyl-n-hydroxyurea compounds having lipoxygenase inhibitory activity
ATE147386T1 (de) * 1991-08-12 1997-01-15 Takeda Chemical Industries Ltd Kondensierte pyrimidinderivate, ihre herstellung und ihre verwendung als antitumormittel
CA2083891A1 (en) * 1991-12-03 1993-06-04 Angus Murray Macleod Heterocyclic compounds, compositions containing them and their use in therapy
JPH05345780A (ja) * 1991-12-24 1993-12-27 Kumiai Chem Ind Co Ltd ピリミジンまたはトリアジン誘導体及び除草剤
US5852046A (en) * 1993-08-03 1998-12-22 Hoechst Aktiengesellschaft Benzo-fused heterocyclic compounds having a 5-membered ring processes for their preparation their use as medicaments their use as diagnostic agents and medicaments containing them
US5350748A (en) * 1993-08-18 1994-09-27 Warner-Lambert Company 3-thio or amino substituted-benzo[b]thiophene-2-carboxamides and 3-oxygen, thio, or amino substituted-benzofuran-2-carboxamides as inhibitors of cell adhesion
DE4425609A1 (de) * 1994-07-20 1996-01-25 Bayer Ag Benzofuranyl- und Benzothienyloxazolidinone
TR199802691T1 (xx) 1997-04-24 1999-07-21 Dow Agrosciences Llc Pestisid etkili 3-(ikameli fenil)-5-(tienil ya da furil)-1,2,4-triazoller
GB9723590D0 (en) 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
FR2777886B1 (fr) * 1998-04-27 2002-05-31 Adir Nouveaux derives benzothiopheniques, benzofuraniques et indoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2336117A1 (en) 1998-06-30 2000-01-06 Sidney Xi Liang Piperidine derivatives having effects on serotonin related systems
WO2000000203A1 (en) 1998-06-30 2000-01-06 Eli Lilly And Company Azepine derivatives having effects on serotonin related systems
US6353008B1 (en) 1998-06-30 2002-03-05 Eli Lilly And Company Pyrrolidine and pyrroline derivatives having effects on serotonin related systems
US6410562B1 (en) * 1998-12-18 2002-06-25 Eli Lilly And Company Hypoglycemic imidazoline compounds
IL144214A0 (en) * 1999-01-13 2002-05-23 Warner Lambert Co Benzoheterocycles and their use as mek inhibitors
JP2000204079A (ja) * 1999-01-13 2000-07-25 Warner Lambert Co ジアリ―ルアミン
FR2799756B1 (fr) * 1999-10-15 2001-12-14 Adir Nouveaux derives benzothiopheniques, benzofuraniques et indoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AR027133A1 (es) 1999-12-30 2003-03-12 Lundbeck & Co As H Derivados de heteroarilo, su preparacion y uso.
AU2001273040A1 (en) 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
IL153817A0 (en) 2000-07-19 2003-07-31 Warner Lambert Co Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
DE10110750A1 (de) * 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
US6653346B1 (en) * 2002-02-07 2003-11-25 Galileo Pharmaceuticals, Inc. Cytoprotective benzofuran derivatives
AU2003217275A1 (en) 2002-02-19 2003-09-09 Pharmacia And Upjohn Company Azabicyclic compounds for the treatment of disease
CA2478534A1 (en) 2002-03-13 2003-09-25 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as mek inhibitors
CA2478374C (en) * 2002-03-13 2009-01-06 Eli M. Wallace N3 alkylated benzimidazole derivatives as mek inhibitors
US20040009976A1 (en) * 2002-04-30 2004-01-15 Kumiko Takeuchi Hypoglycemic imidazoline compounds
GB0214268D0 (en) 2002-06-20 2002-07-31 Celltech R&D Ltd Chemical compounds
CA2494091C (en) 2002-08-02 2011-02-01 Richard B. Toupence Substituted furo [2,3-b| pyridine derivatives
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
CL2003002287A1 (es) * 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
JP2005104838A (ja) 2003-01-09 2005-04-21 Tanabe Seiyaku Co Ltd 縮合フラン化合物
GB0316237D0 (en) 2003-07-11 2003-08-13 Astrazeneca Ab Therapeutic agents
GB0316232D0 (en) 2003-07-11 2003-08-13 Astrazeneca Ab Therapeutic agents
DK1663242T3 (da) 2003-08-07 2011-08-01 Rigel Pharmaceuticals Inc 2,4-Pyrimidindiamin-forbindelser og anvendelse som antiproliferative midler
US7144907B2 (en) * 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
DE10351436A1 (de) 2003-11-04 2005-06-09 Merck Patent Gmbh Verwendung von Thienopyrimidinen
DE602004011985T2 (de) 2003-11-25 2009-03-05 Eli Lilly And Co., Indianapolis Modulatoren des peroxisomproliferatoraktivierten rezeptors
EP1694663A1 (en) 2003-12-19 2006-08-30 Biovitrum Aktiebolag Novel benzofuran derivatives, which can be used in prophylaxis or treatment of 5-ht6 receptor-related disorder
ATE381554T1 (de) 2003-12-22 2008-01-15 Basilea Pharmaceutica Ag Aroylfurane und aroylthiophene, die sich für die behandlung von krebs eignen
EP1699488A2 (en) 2003-12-23 2006-09-13 Pfizer Products Incorporated Therapeutic combination for cognition enhancement and psychotic disorders
AU2006232620A1 (en) * 2005-04-06 2006-10-12 Astrazeneca Ab Substituted heterocycles and their use as CHK1, PDK1 and PAK inhibitors
WO2007027855A2 (en) * 2005-09-01 2007-03-08 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
WO2008024725A1 (en) * 2006-08-21 2008-02-28 Genentech, Inc. Aza-benzofuranyl compounds and methods of use
WO2008028141A2 (en) 2006-08-31 2008-03-06 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof

Also Published As

Publication number Publication date
KR101475088B1 (ko) 2014-12-23
BRPI0714629A2 (pt) 2013-05-07
PE20120049A1 (es) 2012-02-16
IL197060A (en) 2014-12-31
AU2007286807A1 (en) 2008-02-28
PE20081359A1 (es) 2008-11-27
TWI426078B (zh) 2014-02-11
EP2069359A1 (en) 2009-06-17
AU2007286807B2 (en) 2013-03-21
IL197060A0 (en) 2009-11-18
AR062469A1 (es) 2008-11-12
CA2660963A1 (en) 2008-02-28
TW200823222A (en) 2008-06-01
JP5349306B2 (ja) 2013-11-20
EP2069359B1 (en) 2014-11-12
WO2008024724A1 (en) 2008-02-28
ES2528797T3 (es) 2015-02-12
US7893085B2 (en) 2011-02-22
JP2010501584A (ja) 2010-01-21
US20080081821A1 (en) 2008-04-03
MX2009001875A (es) 2009-03-02
KR20090047538A (ko) 2009-05-12
CL2007002431A1 (es) 2008-03-14

Similar Documents

Publication Publication Date Title
NO20091198L (no) Azabenzotiofenylforbindelser og anvendelser derav
NO20091197L (no) Azabenzofuranylforbindelser og anvendelser derav
DK2231662T3 (da) 8-Anilinoimidazopyridiner og deres anvendelse som anticancer- og/eller antiinflammatoriske midler
WO2010003022A8 (en) Isoindolone derivatives as mek kinase inhibitors and methods of use
MY158829A (en) 5-anilinoimidazopyridines and methods of use
WO2008157179A3 (en) N-substituted azaindoles and methods of use
NO20074473L (no) RAF-inhibitorforbindelser og -fremgangsmater
WO2009111278A3 (en) Raf inhibitor compounds and methods of use thereof
SG178986A1 (en) 4-substituted pyridin-3-yl-carboxamide compounds and methods of use
UA111933C2 (uk) Піролопіридини як інгібітори кінази
NO20076553L (no) RAF-inhibitorforbindelser og fremgangsmater for anvendelse derav
WO2009151598A8 (en) Diazacarbazoles and methods of use
UA111756C2 (uk) Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
NO20081595L (no) Raf-inhibitorforbindelser og fremgangsmater for anvendelse derav
WO2011025938A3 (en) Raf inhibitor compounds and methods of use thereof
BR112014021634A8 (pt) inibidores de serina/treonina quinase,composições que os compreendem, seus usos e seus processos de preparação, e método de inibir a atividade da proteína quinase erk em uma célula
NO20083572L (no) Tiazolforbindelser som proteinkinase-B (PKB)-inhibitorer
NO20084927L (no) Fosfoinositid-3-kinaseinhibitorforbindelser og farmasoytiske sammensetninger inneholdende dem
MX2014005282A (es) Compuestos de 8-fluoroftalazin-1 (2h) -ona.
WO2009012109A3 (en) Cyanine-containing compounds for cancer imaging and treatment
ECSP10010507A (es) Pirazolo (3, 4-b) piridina inhibidores de raf
MX2012006822A (es) 1,7-diazacarbazoles y metodos de uso.
NO20084928L (no) Farmasoytiske sammensetninger
WO2010105008A3 (en) Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies
SG178900A1 (en) Raf inhibitor compounds and methods of use thereof

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application